NY-KYNDRYL
20.9.2022 06:02:37 CEST | Business Wire | Press release
Kyndryl (NYSE: KD), the world's largest IT infrastructure services provider, today announced a new open integration platform giving business leaders real-time insights into their complex IT estates, and unprecedented control over customizing their mission-critical operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005855/en/
Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth (Graphic: Business Wire)
Kyndryl Bridge leverages Kyndryl’s core technology strengths. It marshals decades of expertise, operational data patterns and IP to generate actionable insights that redefine how enterprises improve and accelerate their AI-powered analytics and business objectives. In doing so, it creates an uninterrupted path between digital business and the tech that drives it. Kyndryl Bridge is designed to meet customers where they are today, enabling interoperability that maximizes the value of tools they already know and trust.
“Dealing with complexity is what Kyndryl does best, and what customers need most. Kyndryl Bridge will be a way for our customers, and Kyndryl, to run their mission-critical infrastructure and digital transformation journeys better,” said Martin Schroeter, Kyndryl’s Chairman and Chief Executive Officer. “Kyndryl is committed to transforming how IT services are delivered, and Kyndryl Bridge is core to our long-term strategic mission to grow our ecosystem of alliance partners, use tools and IP to create a robust advanced delivery system, and ultimately dedicate more expertise and focus to best serve customers at scale.”
Across the global economy, digital modernization efforts sit at the top of today’s business agendas, with 60 percent of CIOs citing it as their most critical growth driver in 2022. However, business and technology complexity — along with a shortage of critical IT skills — has slowed progress for most enterprises. Kyndryl is accelerating its customers’ digital business journeys by innovating to deliver solutions through platform-enabled services.
“Enterprise IT leaders today are responsible for the management of increasingly-complex IT estates that demand greater oversight, interoperability, and AI-powered analytics to avert challenges and downtime,” says David Tapper, program VP, Outsourcing and Managed Cloud Service at IDC. “The ability of Kyndryl Bridge to connect the many tools, workflows, and processes in which enterprises have spent years investing, while delivering real-time, actionable insights and recommendations, is a powerful proposition for enterprises throughout the global economy.”
Kyndryl Bridge integrates and connects the complex management and process tools that enterprises throughout the global economy rely upon. Its capabilities have, on average, reduced the number of incidents per server per month for enterprises by 74 percent.
“By enabling leaders to focus less on managing IT systems, they can build and support their digital business strategies while freeing up IT resources for higher-value work,” said Antoine Shagoury, Kyndryl’s Chief Technology Officer. “It provides greater access and control over critical tools, and Kyndryl experts in cloud, data and AI, security and resiliency, mainframe modernization, and other important aspects of the IT estate.”
Designed with configurability in mind, Kyndryl Bridge is evolving to deploy ready-made, industrial scale solutions from Kyndryl and its broad and growing partner ecosystem. Its intelligent management tools, powered by automation and AI, will provide technology leaders with real-time insights to prevent downtime and better forecast future needs and costs.
“As customers accelerate their digital transformation, Kyndryl’s new digital integration platform can help provide rich data insights, solutions automation, and services delivery expertise,” said Nick Holden, Vice President, Cisco Global Strategic Partners and Co-sell. “Kyndryl Bridge is a big step forward to enable Kyndryl and Cisco to deliver business outcomes that our joint customers are demanding.”
For customers, the platform maximizes the benefits of native multi-cloud capabilities and delivers an ‘as-a-service’ (aaS) operating environment. It is designed to be a strategic digital hub, that will continue to expand and grow over time, connecting Kyndryl’s advanced technology and tooling with a deep bench of industry expertise and forward-thinking innovators across virtually every sector of the global economy.
About Kyndryl
Kyndryl (NYSE: KD) is the world’s largest IT infrastructure services provider serving thousands of enterprise customers in more than 60 countries. The Company designs, builds, manages, and modernizes the complex, mission-critical information systems that the world depends on every day. For more information, visit www.kyndryl.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
